Chemical Component Summary

NameSPIRONOLACTONE
Synonyms17-HYDROXY-7ALPHA-MERCAPTO-3-OXO-17ALPHA-PREGN-4-ENE-21- CARBOXYLIC ACID; GAMMA-LACTONE ACETATE
IdentifiersS-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxo-spiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate
FormulaC24 H32 O4 S
Molecular Weight416.573
TypeNON-POLYMER
Isomeric SMILESCC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C
InChIInChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
InChIKeyLXMSZDCAJNLERA-ZHYRCANASA-N

Chemical Details

Formal Charge0
Atom Count61
Chiral Atom Count7
Bond Count65
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB00421 
NameSpironolactone
Groups approved
DescriptionSpironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists.[A178192] It promotes sodium and water excretion and potassium retention.[A11837] Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.[A11837, A178246] It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension.[L44602] Off-label uses of spironolactone include hirsutism, female pattern hair loss, and adult acne vulgaris.[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243, L6187]
Synonyms
  • Espironolactona
  • Spironolactone
  • Spironolactonum
  • Spironolattone
Brand Names
  • Dapsone 6% / Niacinamide 2% / Spironolactone 5%
  • Aldactazide
  • Niacinamide 2% / Spironolactone 5% / Tretinoin 0.05%
  • Ntp-spironolactone
  • Qaialdo
IndicationSpironolactone is indicated for the treatment of the following conditions: - NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone is usually administered in conjunction with other heart failure therapies.[L44602] - Hypertension, as add-on therapy, in patients not adequately controlled by other agents.[L44602, L47810] - Edema associated with hepatic cirrhosis when edema is not responsive to fluid and sodium restriction.[L44602, L47810] - Edema associated with nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response.[L44602] - Refractory edema associated with congestive cardiac failure, malignant ascites, hepatic cirrhosis with ascites, and essential hypertension.[L47810] - Short-term preoperative treatment of patients with primary hyperaldosteronism.[L44602, L47810] - Diagnosis of primary aldosteronism.[L47810] - Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery.[L44602] - Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism).[L44602] As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.[A178135, A261025]
Categories
  • Agents causing hyperkalemia
  • Antihypertensive Agents
  • Antihypertensive Agents Indicated for Hypertension
  • BSEP/ABCB11 Substrates
  • Cardiovascular Agents
ATC-CodeC03DA01
CAS number52-01-7

Drug Targets

NameTarget SequencePharmacological ActionActions
Mineralocorticoid receptorMETKGYHSLPEGLDMERRWGQVSQAVERSSLGPTERTDENNYMEIVNVSC...unknownantagonist
Glucocorticoid receptorMDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAV...unknownantagonist
Androgen receptorMEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPP...unknownantagonist
Progesterone receptorMTELKAKGPRAPHVAGGPPSPEVGSPLLCRPAAGPFPGSQTSDTLPEVSA...unknownagonist
Estrogen receptorMTMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPA...unknownagonist
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL1393
PubChem 5833
ChEMBL CHEMBL1393
ChEBI CHEBI:9241
CCDC/CSD ATPRCL01, WUWRIQ, ATPRCL10, WUWROW, WUWREM, UWEWAX, UWEWIF, UWEWAX01, UWEWOL, WUWREM02, HAKTEW, UDEFAO, WUWREM01, WUWRIQ01, UDEDOA
COD 4502456, 4502457, 4502455